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Severe acute respiratory syndrome (SARS) poses a
major threat to the health of people worldwide. We per-
formed a retrospective case series analysis to assess clin-
ical outcome and identify pretreatment prognostic corre-
lates of SARS, managed under a standardized treatment
protocol. We studied 127 male and 196 female patients
with a mean age of 41±14 (range 18–83). All patients,
except two, received ribavirin and steroid combination ther-
apy. In 115 (36%) patients, the course of disease was lim-
ited. Pneumonitis progressed rapidly in the remaining
patients. Sixty-seven (21%) patients required intensive
care, and 42 (13%) required ventilator support. Advanced
age, high admission neutrophil count, and high initial lac-
tate dehydrogenase level were independent correlates of
an adverse clinical outcome. SARS-associated coronavirus
caused severe illnesses in most patients, despite early
treatment with ribavirin and steroid. This study has identi-
fied three independent pretreatment prognostic correlates.
T
he outbreak of severe acute respiratory syndrome
(SARS) in Hong Kong was caused by a novel virus
belonging to the family Coronaviridae (1,2). The virus is
transmitted through respiratory droplets, direct contact
with fomites, and aerosolized respiratory secretions (3,4).
The first outbreak was linked to an index patient treated in
the Prince of Wales Hospital (4). The second wave of
spread in the community was started by an infected patient
with renal disease and amplified by the sewage system of
Amoy Gardens, a densely populated condominium in
Hong Kong (5). The floor drain traps in many apartments
of Amoy Gardens were not filled with water and thus lost
the sealing function. Therefore, the bathrooms of many
apartments were openly connected with the soil stack.
Virus-loaded droplets of an affected apartment could have
been spread through the floor drain system. Hundreds of
patients were then treated in public hospitals. The virus
was highly contagious and caused substantial illness and
death among the general population as well as among
healthcare workers.
The Hong Kong Hospital Authority, which provides
more than 90% of inpatient care in Hong Kong, has been
responsible for the management of all SARS patients (6).
The Princess Margaret Hospital is a designated treatment
center for SARS patients. Convalescent-phase SARS
patients are treated in Wong Tai Sin Hospital. More than
500 SARS patients have been treated in these two hospi-
tals since March 2003. The Hospital Authority has estab-
lished a structured approach in the diagnosis, investiga-
tion, and treatment of SARS. The clinical diagnostic crite-
ria of the Hospital Authority’s SARS registry (defined in
Table 1) were similar to the case definition of probable
SARS by the World Health Organization (3). 
Persons infected with the SARS-associated coronavirus
may exhibit a wide spectrum of signs and symptoms and a
varied clinical course. We have found asymptomatic cases
and patients with spontaneous recovery without antiviral
or steroid therapy; SARS is at the other end of the disease
spectrum. The Hospital Authority’s hypothetical disease
model has three phases: viral replication, immune hyperac-
tivity, and pulmonary destruction (7). Autopsy findings
have supported the theory of cytokine deregulation in
SARS (8). Using steroids in the treatment of SARS was
based on this hypothesis and on initial clinical experience
in the management of SARS in Hong Kong (4).
The recommended treatment regime at the time of the
Amoy Gardens outbreak consisted of antibiotics, ribavirin,
and steroid combination therapy. Patients without known
epidemiologic contact with SARS patients were treated
with antibiotics that would prevent both community-
acquired pneumonia and hospital infections. If patients did
not respond to antibiotics in 48 h, they would be given a
combination of ribavirin and steroid. For patients with an
epidemiologic history of contact with a SARS patient, this
combination would be started together with the above
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intravenously every 8 h. For patients who appeared for
treatment with extensive pneumonitis, a loading dose of 33
mg/kg of ribavirin, followed by 20 mg/kg every 8 h, was
given intravenously. Hydrocortisone, 2 mg/kg every 6 h or
4 mg/kg every 8 h, would be administered, together with
ribavirin. Oral equivalent doses of ribavirin and pred-
nisolone could be prescribed at any stage of the disease.
The total duration of therapy could range from 14 to 21
days. Besides administering steroids, we have tried in
selected cases immunomodulation through the use of intra-
venous pentaglobin. Pulsed doses of methylprednisolone
were restricted to those with disease progression and
marked lung involvement. Lee et al. have made a compre-
hensive report of 138 cases of suspected SARS during a
hospital outbreak in Hong Kong (4). Our study investigat-
ed the SARS patients after the Amoy Gardens outbreak to
identify associated pretreatment prognostic factors for risk
stratification and assess the clinical outcome of SARS
under a standardized treatment protocol.
Methods
We performed a retrospective case series study. All
reported SARS patients who stayed in the medical wards
or intensive care unit of Princess Margaret Hospital and
Wong Tai Sin Hospital on April 16, 2003, were screened.
Patients were excluded if subsequent follow-up serologic
tests showed no rise in antibody titer against SARS-asso-
ciated coronavirus. All eligible SARS patients, except
three, were recruited into the study. One healthcare work-
er refused to be studied, and two patients who were sus-
pected of contracting the infection during their hospital
stay were also excluded. This cohort was followed up until
May 20, 2003. Data were collected through the Hong
Kong Hospital Authority’s computerized clinical manage-
ment system, case record review, and a questionnaire sur-
vey assisted by the nursing staff of each SARS ward. Age,
sex, occupation, residential address, smoking habit, time
between onset of fever and start of antiviral therapy, coex-
isting conditions, and laboratory data were the variables
under study. Outcome variables were the following:
dependency on high amounts of oxygen (requiring at least
3 L/min of oxygen through a nasal cannula) and admission
to an intensive care unit or death. 
Statistical Analysis 
Categorical variables were analyzed with the chi-
square test and the means of continuous variables were
compared with the Student t test. Association among con-
tinuous variables was assessed with Pearson correlation
coefficient. Multivariate logistic regression by backward
stepwise analysis was performed to identify independent
variables that correlated with the clinical outcome as of
May 20, 2003. Cox’s regression model was used to study
survival data. Plus-minus values are mean ± standard devi-
ation; a p value of <0.05 was considered significant, and
all probabilities were two-tailed. SYSTAT software (ver-
sion 10.0, SPSS, Chicago, IL) was used for statistical
analysis.
Results
The study population consisted of 127 male and 196
female patients, ranging in age from 18 to 83 (41±14).
Forty-seven (15%) patients were healthcare workers. One
hundred thirty-three (41%) were Amoy Gardens residents.
Two hundred seventy-three (85%) patients were in good
health. The coexisting conditions are listed in Table 2.
Psychiatric illness, hepatitis B carrier status, and tha-
lassemia trait status were not classified as coexisting con-
ditions. Fifteen (14%) males and 7 (4%) females were cur-
rent smokers. The overall prevalence of smoking among
SARS patients was 7.6% (9.1% if healthcare workers are
excluded). None of the affected healthcare workers
smoked. The symptoms exhibited fulfilled the diagnostic
criteria of the Hospital Authority’s SARS registry.
All patients had lung involvement, documented either
by chest x-ray or high-resolution computed tomographic
scan of the thorax. Lymphopenia, found in 221 (68%)
patients, was a prominent feature in those who sought
treatment. Other initial laboratory findings included
thrombocytopenia (41%), elevated creatine kinase level
(14%), and elevated lactate dehydrogenase level (42%).
Initial bacterial cultures were negative. Virus screening
was negative for adenovirus, respiratory syncytial virus,
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Table 1. Case definition of SARS, Hong Kong Hospital Authority SARS Registry, April 22, 2003  
Inclusion criteria  Exclusion criterion 
Radiographic evidence of infiltrates consistent with pneumonia  A case should be excluded if an alternative diagnosis can 
fully explain the illness 
Temperature >38°C or history of such temperature at any time in the past 2 days   
At least two of the following:   
History of chills in the past 2 days   
Cough (new or increased cough) or breathing difficulty   
General malaise or myalgia   
Known history of exposure   
aSARS, severe acute respiratory syndrome. influenza A and B, and parainfluenza virus. Two hundred
and seven (64%) patients had reverse transcriptase–poly-
merase chain reaction (RT-PCR) assays performed for
SARS-associated coronavirus, and 128 (62%) of the
results were positive. Two hundred and forty-two (75%)
patients had completed serologic testing. The diagnosis of
recent SARS-associated coronavirus infection was con-
firmed by either RT-PCR assays or serologic test in 286
(89%) patients. The sensitivity of RT-PCR assays was 58%
(95% confidence interval [CI], 50% to 66%).
Our patients sought treatment 3.9±2.7 days after onset
of fever. The interval between onset of fever and admission
was positively correlated with admission neutrophil count
(Pearson r=0.1, p=0.07), admission platelet count (Pearson
r=0.1, p=0.06), and initial lactate dehydrogenase level
(Pearson r=0.36, p<0.001). An antibiotic was started
immediately after admission in all cases. Either lev-
ofloxacin, 500 mg once a day, or amoxicillin/clavulinate
acid, 375 mg three times a day plus clarithromycin, 500
mg twice a day, was used to protect against community-
acquired pneumonia. All patients were also treated with
oral or intravenous ribavirin, according to protocol. Most
(94%) were given either intravenous hydrocortisone or
oral prednisolone, according to protocol. Five patients
received intravenous methylprednisolone as a form of
steroid therapy. The dose was administered at 3 mg/kg
once a day and would be tapered down to 1 mg/kg if the
patient showed a clinical response. Pulsed doses of
methylprednisolone (500 mg per dose) were given as ini-
tial treatment in 12 patients, who then received mainte-
nance steroid therapy. Two patients were treated with rib-
avirin only. Ribavirin plus steroid therapy was adminis-
tered 1.2±1.7 days after admission. The interval between
admission and initiation of antiviral therapy was negative-
ly correlated with the interval between onset of fever and
admission (Pearson r = –0.17, p=0.003).
Clinical Outcome
In 115 (36%) patients, the disease was limited with res-
olution of fever and pneumonitis. Two hundred and eight
(64%) patients had either clinical or radiologic evidence of
progression of pneumonitis, and they received 2.9±2 gm
pulsed dose methylprednisolone therapy. Maintenance
steroid was resumed after pulsed dose therapy. Patients
who were given pulsed doses of steroids were treated with
potent broad-spectrum intravenous antibiotics (piperacillin
and tazobactam) to protect against hospital-acquired infec-
tion. Hyperglycemia, hypokalemia, flare up of hepatitis B
infection, hospital-acquired infection, and steroid psy-
chosis were the acute side effects encountered. Hepatitis B
carriers were treated with lamivudine, 100 mg once a day;
no liver failure occurred in  members of this cohort.
Disease progression was apparently arrested by pulsed
dose steroid therapy in 98 (30%) patients. In the remaining
110 (34%) patients, the illness ran a severe and protracted
course, and the patient needed high doses of oxygen.
Sixty-seven (21%) had been admitted to intensive care
unit, and 42 (13%) required ventilator support. Twenty-six
patients died (12 males and 14 females). The crude mortal-
ity rate of our cohort after 47±8 days of follow-up was
7.9% (95% CI, 5% to 10.8%) and was an underestimation
because of sampling bias. Those who died before April 16,
2003, were excluded from our sample, while long-term
survivors were retained for study. Among them, 10 had
concurrent medical illness. No healthcare worker in this
cohort died. Diabetes was found in three patients who died,
and hypertension in four who died. Eleven of those who
died lived in Amoy Gardens. A young pregnant woman
died after delivery, despite aggressive treatment.
Age, sex, healthcare worker status, Amoy Gardens res-
ident status, presence of coexisting conditions, interval
between onset of fever and therapy (ribavirin plus steroid),
neutrophil and platelet count on admission, and initial cre-
atine kinase and lactate dehydrogenase levels were the cor-
relates of clinical outcome under study. Variables with a p
value of <0.1 by univariate analysis were entered into the
multivariate regression model. By multivariate logistic
regression, advanced age, high neutrophil count on admis-
sion, and high initial lactate dehydrogenase level were
independent correlates of high oxygen dependency as well
as intensive care unit admission or death (Table 3). By
Cox’s backward stepwise regression, young age, low neu-
trophil count on admission, and healthcare worker status
(p=0.05) were favorable independent correlates of survival
time (Table 3). A dose-response relationship also existed
between the independent correlates and clinical outcome
(Figures 1–3). We used the term “correlates” instead of
“predictors” of outcome because of the method we used, a
case series.
The second serology titer obtained after the end of sec-
ond week was negatively correlated with age (Pearson
r=–0.13, p=0.05) and admission lymphocyte count
(Pearson r=–0.17, p=0.01). Conversely, the neutrophil
count on admission was positively correlated with the sec-
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Table 2. Coexisting conditions in patients with severe acute 
respiratory syndrome 
Coexisting condition  No. of patients 
Hypertension  16 
Diabetes mellitus  8 
Chronic lung disease  6 
Pregnancy  5 
Neurologic disease  5 
Renal disease  4 
Cardiovascular disease  3 
Immunologic disease  3 
Malignancy  1 
 ond serology titer (Pearson r=0.2, p=0.003). The pulsed
dose of steroid was not shown to affect the second serolo-
gy titer (Pearson r=0.1, p=0.18). Patients who depended on
high oxygen therapy had a higher second antibody titer
against SARS-associated coronavirus (p = 0.05).
Discussion
The virus attacked persons of both sexes and all ages.
Many were previously in good health and the wage earn-
ers in their families. Not infrequently, several members of
a family were admitted to the hospital. The need for isola-
tion discouraged close social contact. Unfortunately, some
of the patients were also stigmatized. The psychosocial
effect of SARS is by no means a lesser problem. 
RT-PCR assay for SARS-associated coronavirus is a
new test, and its sensitivity and specificity have yet to be
established. In our cohort, the sensitivity was  58%, and
results depended on sampling technique and stage of dis-
ease (9). Contamination of specimen could lead to a false-
positive result. A false-negative result could arise from
performing the test in the very early or late stage of the dis-
ease. Diarrhea was common among Amoy Gardens SARS
patients. The virus could be found in stool by RT-PCR
assays. A negative test does not rule out the diagnosis,
however. The serologic test remains as the standard crite-
rion of definitive diagnosis. Pulsed doses of steroid did not
seem to affect the humoral response of SARS patients. In
retrospect, the intensity of antibody response was related
to clinical outcome and associated pretreatment prognostic
factors. The viral load could be a determinant of these
prognostic association factors.
Our hematologic and biochemical data, as well as asso-
ciated prognostic factors, agreed with the work of Lee et
al. (4). Both advanced age and high neutrophil count on
admission were associated with poor outcome. We found
that initial lactate dehydrogenase level was also an associ-
ated prognostic factor. The early phase of SARS is charac-
terized by lymphopenia and thrombocytopenia. As the dis-
ease progresses, both neutrophil and platelet counts rise,
accompanied by an elevation in lactate dehydrogenase
level. The neutrophilic response is important in the patho-
genesis of hypersensitivity pneumonitis, and thus the ini-
tial neutrophil count could also indicate disease progres-
sion. Lactate dehydrogenase level reflects tissue necrosis
related to immune hyperactivity in SARS and thus relates
to poor outcome. Patients with high neutrophil counts and
lactate dehydrogenase levels on admission could have
been late in seeking treatment or have experienced heavy
exposure to the virus. 
Effect on Healthcare Workers 
The spread of the disease to healthcare workers is a
major problem in any country dealing with SARS.
Intubation, nasopharyngeal aspiration, chest physiotherapy,
handling of excreta, and even feeding become high-risk
procedures. All healthcare workers working in Hospital
Authority hospitals are required to follow the recommend-
ed personal protection equipment standards (10). The level
of precaution depends on the risk in the work area and the
type of procedure performed. All healthcare workers work-
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Table 3. Independent prognostic correlates and clinical outcome 
  High oxygen dependency  ICU care or death  Survival time 
Correlates  OR (95% CI) p value  OR (95% CI) p value  Hazard ratio (95% CI) p value 
Age (per 10-y increase)  1.48 (1.21 to 1.8) p<0.001  1.57 (1.26 to 1.95) p<0.001  1.75 (1.38 to 2.2) p<0.001 
Admission neutrophil (per 1x10
9/L increase)  1.31 (1.14 to 1.5) p<0.001  1.28 (1.13 to 1.46) p<0.001  1.17 (1.09 to 1.26) p<0.001 
Initial LDH level (per 100 IU/L increase)  1.49 (1.23 to 1.82) p<0.001  1.35 (1.11 to 1.64) p=0.003  p value not significant 
aICU, intensive care unit; LDH, lactate dehydrogenase; OR, odds ratio; CI, confidence interval.   
Figure 1. Relationship between age and fatal severe acute respi-
ratory syndrome illness, Hong Kong, 2003. 
Figure 2. Relationship between neutrophil count and fatal severe
acute respiratory syndrome illness, Hong Kong, 2003. 
Figure 3. Relationship between lactate dehydrogenase level
(LDH) and fatal severe acute respiratory syndrome illness, Hong
Kong, 2003ing in a SARS area wore N-95 masks, face shields, caps,
gowns, and surgical gloves. The intensive care unit was
high-risk area in this cohort (Table 4). However, healthcare
workers working in a non-SARS area were not exempted.
They contracted the disease from SARS patients who
sought treatment early or exhibited atypical signs and symp-
toms. By univariate analysis, healthcare worker status was
negatively correlated with death. Healthcare workers were
younger. They sought treatment earlier and had a lower neu-
trophil count and lower initial lactate dehydrogenase level
on admission (Table 5). Nevertheless, healthcare worker
status was still an independent survival correlate after con-
trolling these confounding variables. The current safety pre-
caution could not prevent all frontline healthcare workers
from contracting SARS, but minimizing individual expo-
sure to the virus might reduce the viral load, subsequent
immune hyperactivity, and the risk for a fatal outcome.
Benefit of Treatment
Most of the patients in this cohort were treated accord-
ing to protocol. The clinical outcome did not represent the
natural history of SARS. The only variable that was related
to the benefit of treatment was the time from onset to treat-
ment. Donnelly et al. found that the time between the onset
of symptoms and admission to hospital did not affect the
death rate (11). In this study, patients who sought treatment
early and received antiviral and steroid combination thera-
py were not shown to do better by multivariate analysis.
The Hospital Authority adopted an aggressive treat-
ment protocol during the peak of the SARS epidemic in
Hong Kong. Broad-spectrum antibiotics and a combina-
tion of ribavirin and steroid were the mainstays of treat-
ment. The dose of ribavirin used was small to prevent
major side effects. The administration of steroids in SARS
treatment is controversial, however. Theoretically, the
early use of steroids promotes viral replication, enhances
infectivity, and possibly causes a rebound of infection.
Peiris et al. found that the viral load peaked at day 10 in
SARS patients treated with both ribavirin and steroids
(12). However, immunosuppression or, more precisely,
immunomodulation, is believed to be an effective therapy
at the second stage of SARS. The current consensus among
the Hospital Authority’s expert panel is to begin adminis-
tering a steroid or pentaglobin at the second stage of SARS
when a hypersensitivity immune reaction occurs (7).
Patients who sought treatment early tended to receive
antiviral therapy at a later time. This is understandable
since the symptoms of SARS are nonspecific, and clini-
cians also rely on laboratory data for diagnosis. The sensi-
tivity of current RT-PCR assays is not satisfactory. A more
sensitive and rapid diagnostic test must be developed, par-
ticularly if we have an effective treatment regime in the
future. 
Conclusion
One third of the SARS patients in our study had a lim-
ited disease course. In the remaining two thirds, pneumoni-
tis progressed rapidly after the early use of ribavirin and
steroid combination therapy. Apparently, approximately
one third responded to pulsed doses of steroids, while the
other third depended on treatment with high amounts of
oxygen. Intensive care was required for 21% of patients.
Advanced age, high neutrophil count on admission, and
elevated initial lactate dehydrogenase level were inde-
pendent correlates of an adverse clinical outcome. Strong
evidence to support early and routine use of ribavirin and
steroid combination therapy in all SARS patients does not
exist. 
We need to investigate new antiviral agents and test the
efficacy of steroids in randomized controlled trials. SARS
is an entirely new emerging disease and its clinical course
varies widely. By stratifying our patients according to risk,
we could individualize our treatment protocol. In addition,
we need a more sensitive and rapid diagnostic test for
SARS-associated coronavirus infection, both for treatment
and for forming cohorts of patients infected with this dead-
ly disease. 
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